Background: A better understanding of the means by which topical vitamin D analogues exert their therapeutic effect on psoriasis is of theoretical and practical importance. Objective: We sought to clarify whether and how the topical vitamin D analogue calcipotriol (CAL) controls the IL-17A-mediated pathogenesis of murine psoriasis-like dermatitis in vivo. Methods: Psoriasis-like dermatitis was induced by the topical application of an imiquimod (IMQ)-containing cream on the murine ear for 4 to 6 consecutive days. For topical CAL treatment, mice were treated daily with CAL solution on the ear before IMQ application. Results: Mice treated topically with CAL exhibited much milder IMQ-induced psoriasis-like dermatitis compared with vehicletreated mice, with impaired accumulation of IL-17A-committed T (T17) cells in the lesional skin. The IMQ-induced upregulation of Il12b and Il23a was marked in the epidermis and was abrogated by CAL application, suggesting CALmediated suppression of IL-23 expression. CAL inhibited Il12b and Il23a expression by Langerhans cells ex vivo stimulated with IMQ and CD40 cross-linking. Topical CAL also inhibited T17 cell expansion in the draining lymph nodes of IMQ-treated skin, implying a possible effect on T17 cell-mediated dermatitis at distant sites. In fact, topical CAL application on the IMQ-treated left ear resulted in amelioration of T17 cell accumulation and psoriasis-like dermatitis in the right ear subsequently treated with IMQ. Conclusion: Topical CAL can exert its antipsoriatic effect on CAL-treated lesions and, concomitantly, distant lesions by
Psoriasis is a common chronic inflammatory skin disease characterized by red scaly papules and plaques, with a prevalence generally estimated at 1% to 3% of the population worldwide. [1] [2] [3] [4] [5] Although the complex pathogenesis of psoriasis remains incompletely understood, compelling evidence suggests that this skin disorder is mediated by the pathologic cross-talk between epidermal keratinocytes and immune cells. 4, 6 Psoriatic keratinocytes produce proinflammatory mediators that contribute to the recruitment and activation of immune cells, such as IL-8, CXCL1, CCL20, and S100A proteins. 1, 3 Conversely, activated immune cells that accumulate in psoriatic skin form a cytokine milieu that induces psoriatic keratinocyte phenotypes.
Among various propsoriatic cytokines, the immunologic pathway involving IL-23 and IL-17A (IL-23/IL-17A axis) has been demonstrated to play a pivotal role in the pathogenesis of psoriasis. 1, 7, 8 IL-23 derived from inflammatory dendritic cells (DCs) stimulates IL-17A-committed T (T17) cells to survive, proliferate, and produce IL-17A and IL-22, which, in turn, act on epidermal keratinocytes to undergo excessive proliferation and impaired differentiation, thereby producing the appearance of psoriatic skin. Understanding how current treatments inhibit the pathogenic processes of psoriasis is of theoretical and practical importance in improving the management of this disease. Vitamin D analogues, such as calcipotriol (CAL), tacalcitol, and maxacalcitol, have been shown to be effective and safe in the topical treatment of psoriasis by previous randomized controlled studies, although they are not effective enough to achieve almost clear psoriatic symptoms. [9] [10] [11] [12] [13] [14] [15] Currently, they are regarded as one of the first-line treatments in guidelines for the management of psoriasis. [16] [17] [18] However, the precise mechanism by which topical vitamin D analogues exert their antipsoriatic effect in vivo remains unknown. The biological effects of the active vitamin D metabolite 1a,25-dihydroxyvitamin D 3 (calcitriol) are mediated by the nuclear vitamin D receptor, which functions as a ligand-activated transcription factor and regulates activation or repression of gene transcription. 19 The vitamin D receptor is expressed in many cell types, including keratinocytes, DCs, and T lymphocytes, [20] [21] [22] [23] which are significantly involved in the pathogenesis of psoriasis. [1] [2] [3] [4] [5] Calcitriol and its analogues suppress the proliferation of keratinocytes and their production of psoriasis-related proinflammatory molecules, including IL-6, IL-8, S100A7, and S100A15 in vitro. [24] [25] [26] Accordingly, topical vitamin D analogues have been considered to improve psoriatic lesions by these direct effects on psoriatic keratinocytes. In addition, it is thought that the immunomodulating properties of vitamin D analogues might also be associated with their role in treating psoriasis. A number of in vitro studies have demonstrated that calcitriol and its analogues inhibit the differentiation and maturation of DCs derived ex vivo from either human peripheral blood monocytes [27] [28] [29] [30] [31] [32] [33] [34] or mouse bone marrow cells. 35, 36 In addition, calcitriol can induce DCs to have in vitro and in vivo tolerogenic properties. 23, [36] [37] [38] [39] Their tolerogenic properties are associated at least in part with attenuated expression of costimulatory molecules, such as CD86 and CD40; decreased IL-12 and IL-23 production; and enhanced IL-10 production. 27, 33, 34, 40 Moreover, calcitriol and its analogue CAL act directly on CD4
1 T cells to suppress T17 cell differentiation and induce preferential differentiation into regulatory T cells and T H 2 cells in vitro. 40, 41 Thus it is theoretically possible that the antipsoriatic effects of topical vitamin D analogues might be due in part to their effects on immune cells. In fact, several studies 42, 43 indirectly imply a possible inhibitory effect of topical vitamin D analogues on IL-23 and IL-17A expression in lesional skin of patients with psoriasis; however, it has not yet been clearly shown whether topical vitamin D analogues actually control the immune pathogenesis of psoriasis in vivo. In addition, topical vitamin D analogues are generally regarded as local symptomatic treatments, and their effects on the systemic pathogenesis of psoriasis remain to be addressed.
Here we investigated whether and how the topical vitamin D analogue CAL controls the IL-17A-mediated pathogenesis of psoriasis in vivo by using a murine model of psoriasis in which psoriasis-like skin inflammation is critically mediated by the IL-23/IL-17A axis. We found that topical CAL application inhibited T17 cell accumulation in not only CAL-treated lesions but also draining lymph nodes (dLNs), leading to attenuated psoriasis-like skin inflammation in CAL-treated lesions and, concomitantly, distant lesions.
METHODS

IMQ-induced psoriasis-like dermatitis and topical CAL application
Murine psoriasis-like dermatitis was induced by topical application of imiquimod (IMQ), a ligand for Toll-like receptor 7, as described previously 44, 45 with modifications. Briefly, B6 mice were treated topically with 10 mg of an IMQ-containing cream (5%; Beselna; Mochida Pharmaceutical, Tokyo, Japan) on each ear for 6 consecutive days, unless otherwise stated. For CAL treatment in mice with IMQ-induced dermatitis, mice were treated daily with 0.2 nmol of CAL (Tocris Bioscience, Bristol, United Kingdom) dissolved in 20 mL of ethanol (EtOH) on the ear 15 minutes before IMQ application.
Other methods
See the Methods section in this article's Online Repository at www. jacionline.org.
RESULTS
Topical CAL application ameliorated IMQ-induced psoriasis-like dermatitis
To examine whether topical CAL application can control the IL-17A-mediated pathogenesis of psoriasis in vivo, we used an IMQinduced murine psoriasis-like dermatitis model because this model is critically dependent on IL-17A derived from T cells, 46, 47 as is human psoriasis. 2, 3 We first confirmed that the topical application of CAL ameliorated IMQ-induced psoriasis-like dermatitis, as demonstrated in human psoriatic lesions. 48, 49 Mice were treated topically with an IMQ-containing cream after either CAL (IMQ/CAL) or vehicle (IMQ/EtOH) on the ears for 6 consecutive days. Because the topical application of CAL on murine skin at the same concentration as in the clinically used CAL lotion (about 121 mmol/L) induced atopic dermatitis-like skin inflammation, 50 CAL was applied at a lower concentration (10 mmol/L) in this study.
IMQ/EtOH treatment induced ear swelling (Fig 1, A) and psoriasis-like lesions characterized by redness, scaling, and crust formation (Fig 1, B) , as previously described. 47, 51 By contrast, mice treated with IMQ/CAL showed significantly decreased ear swelling (Fig 1, A) and much milder inflammation phenotypically (Fig 1, B) compared with IMQ/EtOH-treated mice. Histologic examination revealed that topical CAL application substantially attenuated epidermal hyperplasia, one of the histologic hallmarks of psoriatic skin lesions, in IMQ-treated skin (Fig 1, C and D , upper panels). In addition, a significantly smaller proportion of epidermal keratinocytes in IMQ/CAL-treated skin were positive for the proliferation marker Ki-67 compared with those in IMQ/EtOH-treated skin (Fig 1, C, lower panels) , indicating that IMQ-induced hyperproliferation of keratinocytes was attenuated by topical CAL application. Moreover, CAL also suppressed inflammatory cell accumulation in the lesional skin of mice with IMQ-induced dermatitis (Fig 1, C, upper panels) , which was further confirmed by flow cytometric analyses of CD45 1 leukocyte numbers (Fig 1, E) .
Taken together, these results suggest that the IMQ-induced murine psoriasis model reflects the response to topical CAL application observed in patients with psoriasis. Thus it is worthwhile to investigate how the treatment exerts its therapeutic effect on psoriasis.
Topical CAL application inhibited accumulation of T17 cells in IMQ-treated skin
Using these experimental settings, we examined whether topical CAL application inhibited the IL-17A-mediated pathogenesis of psoriasis-like dermatitis. Quantitative RT-PCR analysis revealed that although the mRNA expression of Il17a was induced in IMQ-treated skin, IMQ-induced Il17a and their means 6 SDs (bars). a.u., Arbitrary units. *P < .05, **P < .01, and ****P < .0001.
J ALLERGY CLIN IMMUNOL VOLUME 141, NUMBER 3 upregulation was markedly suppressed by topical CAL application (Fig 2, A) . CAL also suppressed the IMQ-induced expression of IL-22, which is known to act on keratinocytes alone or in synergy with IL-17A to promote development of the psoriatic phenotype in mice, as well as in human subjects, 44, 47, [52] [53] [54] at the mRNA level (Fig 2, A) . In line with the attenuated expression of Il17a, IMQ/CAL-treated skin showed markedly decreased expression of genes encoding the antimicrobial molecules with orthologues known to be overexpressed in human psoriatic skin and induced in keratinocytes stimulated with IL-17A 55,56 compared with IMQ/EtOH-treated skin (see Fig E1 in this article's Online Repository at www.jacionline.org). By contrast, expressions of T H 1-, T H 2-, and regulatory T cell-related genes were not affected by CAL application (Fig 2, A) . Flow cytometric analysis showed that IMQ treatment led to a marked increase in the number of T17 cells in the Vg4 1 subset of dermal gd T cells but not in the ab T-cell and Vg4 2 dermal gd T-cell subsets (Fig 2, B and C, and see Fig E2 in this article's Online Repository at www.jacionline.org), which was consistent with previous reports. 47, 57 IMQ-induced accumulation of Vg4 1 gd T17 cells was strongly attenuated by topical CAL application (Fig 2,  B and C) . CAL application also suppressed the increase in the number of IL-22-committed T-cell populations in IMQ-treated skin (Fig 2, B and D) .
Collectively, these results suggest that topical CAL application inhibits the IL-17A-mediated pathogenesis of psoriasis-like dermatitis by attenuating accumulation of pathogenic T17 cells in lesional skin.
Topical CAL application suppressed IL-23 expression in IMQ-treated skin
Previous studies have revealed that T17 cell expansion is promoted by IL-23 in both mice [58] [59] [60] and human subjects.
61-63
Thus we hypothesized that CAL-mediated inhibition of T17 cell accumulation in lesional skin of mice with IMQ-induced dermatitis was attributed to attenuated IL-23 expression. Quantitative RT-PCR analysis revealed that mRNA expression of the Il12b and Il23a genes, which encode the IL-12/IL-23p40 and IL-23p19 subunits of IL-23, respectively, was markedly increased in the epidermis in mice with IMQ/EtOH-treated skin compared with EtOH-treated skin (Fig 3, A) . By contrast, Il12a, which encodes the IL-12p35 subunit, was not significantly induced by IMQ treatment (Fig 3, A) , suggesting that expression of IL-23, but not IL-12, was upregulated in the epidermis in mice with IMQ-treated skin. Il12b and Il23a expression in the epidermis was significantly less in IMQ/CAL-treated skin than in IMQ/EtOH-treated skin (Fig 3, A) . IMQ-induced upregulation of Il12b and Il23a was also observed in the dermis, although much less markedly, and was suppressed by CAL application (Fig 3, A) . An ELISA revealed that IMQ-induced expression of IL-12/IL-23p40 protein in the epidermis was significantly inhibited by CAL (Fig 3, B) , corroborating that IL-23 expression in the setting of IMQ-induced dermatitis was suppressed by CAL application. Given the previous findings that induction of the Il17a expression, T17 cell accumulation, and a psoriasislike phenotype in this model are completely abolished in Il23a-deficient mice, 46, 51, 64 the CAL-mediated suppression of IL-23 expression is likely to contribute substantially to the attenuation of the T17 cell accumulation in IMQ-treated skin.
To further confirm the inhibitory effect of CAL on IL-23/IL-17A-mediated skin inflammation, we started CAL application on IMQ-treated skin at day 3, when IMQ-induced skin inflammation had already developed, and assessed expression levels of Il17a, Il22, Il23a, and Il12b at day 6. mRNA levels of these genes were suppressed by CAL treatment (see Fig E3 in RT-PCR analysis of Il23a, Il2b, and Il12a in the epidermis and dermis of the lesional skin. B, Measurement of IL-12/23p40 protein levels in lesional epidermis by using ELISA. All samples were collected 24 hours after 4 applications of the indicated chemicals. Data are shown as each value (symbols) and their means 6 SDs (bars). a.u., Arbitrary units. **P < .01, ***P < .001, and ****P < .0001.
CAL inhibited the differentiation of IL-23-competent mature Langerhans cells and suppressed IL-23 expression by mature Langerhans cells ex vivo
Although the predominant cell source for IL-23 in the setting of IMQ-induced dermatitis is still under debate, [64] [65] [66] our previous study has indicated the essential role of IL-23 derived from epidermal Langerhans cells (LCs) in the pathogenesis of this psoriasis model. 65 Consistent with this, mRNA levels of Il12b and Il23a were markedly increased in the epidermis of IMQ-treated skin. Thus we next explored how topical CAL suppressed IL-23 expression by LCs.
To this end, we first asked whether the CAL-mediated suppression of Il12b and Il23a expression in the epidermis was due to the direct effects of CAL on epidermal cells rather than being merely secondary to attenuated dermal inflammation. We cultured epidermal sheets separated from untreated murine ear skin in the absence or presence of CAL for 3 days, isolated migratory LCs in the culture media, and assessed their Il12b and Il23a expression after stimulation (see Fig E4, (Fig 4,  A) , as previously reported in DCs. 68 By contrast, migratory LCs from epidermal explants cultured in the presence of CAL did not upregulate Il12b and Il23a in response to IMQ plus CD40 antibodies (Fig 4, A) . This defect was due to neither insufficient activation nor attenuated CD40 cross-linking because CAL-treated LCs expressed CD86, CD80, and CD40 at equivalent amounts as control LCs (data not shown). These results suggest that CAL acts on epidermal cells, such as LCs and keratinocytes, to inhibit immature LCs from gaining IL-23 competency during their maturation.
Next, we asked whether CAL can also suppress IL-23 expression by already matured IL-23-competent LCs. Migratory LCs isolated from epidermal explants were cultured in the presence or absence of CAL for 29 hours and stimulated for the last 5 hours of culture with IMQ and CD40 antibodies (see Fig E4, B) . Expression of Il12b and Il23a, but not Il12a, was induced in mock-treated LCs by IMQ and CD40 antibodies, although IL-23 protein concentrations in the culture supernatant were less than the limit of detection of ELISA (Fig 4, B) . Induction of Il12b and Il23a expression was significantly suppressed in CAL-treated LCs compared with mock-treated LCs (Fig 4, B) . Induction of Il6 was also suppressed in CAL-treated LCs, whereas that of Tnf was not, excluding that CAL-treated LCs have a general defect in proinflammatory responses (see Fig E6 in this article' s Online Repository at www.jacionline.org).
Taken together, we established an in vitro assay for assessing IL-23 expression by murine LCs, which revealed that CAL can inhibit the differentiation of IL-23-competent mature LCs by acting on epidermal cells and also can suppress IL-23 expression by mature LCs directly.
Topical CAL application on IMQ-treated skin resulted in impaired expansion of T17 cells in dLNs
Several human studies have suggested a pathogenic role of CCR6-expressing T17 cells that infiltrate from the blood into psoriatic skin lesions, where CCL20, a ligand for CCR6, is highly expressed. 4, 69, 70 In the IMQ-induced murine psoriasis model, it has been reported that the CCR6 1
Vg4
1 gd T17 cell population expands considerably in dLNs of IMQ-treated skin and homes to inflamed skin, which can accelerate psoriasis-like dermatitis. 45 Thus we next examined whether topical CAL application could control the IMQ-induced expansion of this pathogenic T-cell population in the dLNs. CCR6 
1 gd T17 cells markedly expanded in the dLNs of the IMQ/EtOH-treated ear, as previously reported, 65, 71 whereas increases in the numbers of ab T17 and Vg4 2 gd T17 cell populations were minimal (Fig 5) . Expansion of the CCR6 1 Vg4 1 gd T17 cell population was much less vigorous in IMQ/CAL-treated mice compared with that in IMQ/EtOH-treated mice (Fig 5) .
These results suggest that topical CAL application on IMQ-treated skin can inhibit the expansion of the CCR6 Topical CAL application on IMQ-treated skin showed a concomitant suppressive effect on psoriasis-like inflammation at a distant site
It has been shown that Vg4 1 gd T17 cells expanding in the dLNs of one psoriasis-like skin lesion can not only home to the initiating site of skin inflammation but can also accumulate in a distant site, where they can accelerate the development of psoriasis-like skin inflammation. 72, 73 Thus we reasoned that CAL-mediated inhibition of T17 cell expansion in the dLNs could lead to amelioration of psoriasis-like skin inflammation at a distant site. To test this hypothesis, mice that had been pretreated with EtOH, CAL, IMQ/EtOH, or IMQ/CAL for 5 days on the left Mice pretreated with IMQ/EtOH on the left ear exhibited more rapid swelling of the right ear after IMQ treatment compared with EtOH-pretreated mice (Fig 6, A) . In addition, the more severe swelling of the right ear observed in IMQ/EtOHpretreated mice was associated with markedly increased accumulation of Vg4 1 gd T17 cells (Fig 6, B) , suggesting exacerbation of T17 cell-mediated psoriasis-like inflammation. By contrast, mice pretreated with IMQ/CAL on the left ear showed significantly attenuated swelling of the IMQ-treated right ear and decreased accumulation of Vg4 1 gd T17 cells compared with IMQ/EtOH-pretreated mice (Fig 6, A and B) , whereas expression levels of Il23a and Il12b were equivalent (see Fig  E8 in this article' s Online Repository at www.jacionline.org). Pretreatment on the left ear with CAL alone did not ameliorate IMQ-induced dermatitis and Vg4 1 gd T17 cell accumulation on the right ear (Fig 6) , further confirming that the concomitant suppressive effect of CAL on psoriasis-like dermatitis at a distant site was not due to systemic immunosuppression by CAL absorbed from the left ear skin into the circulation.
DISCUSSION
The present study provides in vivo evidence that the topical vitamin D analogue CAL can inhibit the IL-17A-mediated pathogenesis of psoriasis by attenuating accumulation of pathogenic T17 cells not only in lesional skin but also in dLNs.
The CAL-mediated inhibition of T17 cell accumulation in human psoriatic lesions has recently been implicated by analyses using the ex vivo expansion of skin-infiltrating T cells with anti-CD3/CD28 antibodies and IL-2. 74 Our results obtained by means of unbiased identification of T17 cells in skin corroborate the in vivo suppressive effect of topical CAL on T17 cell accumulation in psoriatic lesions. In addition, we found that topical CAL application suppresses the expansion of T17 cells in the dLNs and leads to concomitant amelioration of psoriasis-like inflammation at a distant untreated site. These results suggest that topical CAL treatment has the potential to prevent the development, exacerbation, and recurrence of psoriatic lesions, even at untreated sites, by reducing the systemic burden of pathogenic T17 cells.
Sun and colleagues 75 have assessed the effect of CAL on IMQ-induced psoriasis-like skin inflammation and observed that CAL treatment did not inhibit but rather exacerbated swelling and inflammation of the IMQ-treated ear. In their study mice were treated twice daily with 40 mg/cm 2 of 0.005% CAL ointment (about 4.85 nmol on each ear). Given that mice treated once daily with 2 to 4 nmol of CAL on each ear have significant ear swelling and atopic dermatitis-like skin inflammation, 50, 76, 77 it is highly likely that CAL-induced skin inflammation compensated the inhibitory effect of CAL on IMQ-induced psoriasis-like inflammation. By contrast, in this study we treated mice once daily with a much lower amount (0.2 nmol on each ear) of CAL to avoid development of CAL-induced skin inflammation and observed a significant inhibitory effect on IMQ-induced psoriasis-like inflammation.
Our results suggest that the CAL-mediated inhibition of T17-mediated pathogenesis is significantly due to the attenuated IL-23 expression by lesional skin DCs, LCs in particular, in the setting of IMQ-induced psoriasis-like dermatitis. Ex vivo experiments revealed that CAL can suppress IL-23 expression in LCs through at least 2 different mechanisms. One mechanism involves inhibiting immature LCs from gaining IL-23 competency during their maturation by acting on epidermal cells, such as keratinocytes, intraepidermal T cells, and LCs. Another mechanism is through direct inhibition of IL-23 expression by IL-23-competent mature LCs. Given the previous report 78 that calcitriol-mediated IL-12 inhibition involves binding of the vitamin D receptor/retinoid X receptor complex to the nuclear factor kB site in the promoter of Il12b, this mechanism likely underlies the inhibition of IL-23 expression by CAL. In addition to the effect on IL-23 expression, the suppressive effect of CAL on IL-17A production from human T cells ex vivo stimulated with anti-CD3 antibodies has been previously described. 74 It is possible that this suppressive activity can also be associated with the antipsoriatic effect of CAL. Thus topical CAL acts through multiple processes to inhibit the T17-mediated pathogenesis of psoriasis.
We have found that topical CAL inhibited T17 cell expansion in the dLNs and ameliorated psoriasis-like inflammation at a distant untreated site. These results suggest that topical CAL not only provides local symptomatic benefit but can also contribute to better control of systemic disease activities in patients with psoriasis by reducing the systemic burden of pathogenic T17 cells. We hypothesized that CAL-mediated inhibition of T17 cell expansion in dLNs is attributed to the attenuated migration of LCs and DCs from the skin to the dLNs, their impaired IL-23 expression, or both. However, the IMQ-induced increase in the number of CD11c SDs (bars). *P < .05, **P < .01, ***P < .001, and ****P < .0001.
J ALLERGY CLIN IMMUNOL VOLUME 141, NUMBER 3 DCs in the dLNs was not affected by topical CAL treatment (data not shown). mRNA amounts of Il12b and Il23a were less than the detection limit of quantitative RT-PCR, even in the dLNs of IMQ-treated skin (data not shown). Thus the mechanism underlying the CAL-mediated inhibition of the T17 cell expansion in dLNs remains to be addressed in future research.
In conclusion, the results of this study provide the immunologic underpinnings of topical vitamin D analogues in the treatment of psoriasis.
Preparation of epidermal and dermal samples for RNA extraction and ELISA Mouse ears were cut off at the base and separated into dorsal and ventral halves by using forceps. The dorsal halves were frozen in liquid nitrogen and used in the experiments. Epidermal samples were taken by shaving the surface of the ear skin with a scalpel in the cryostat at 2308C. After shaving the epidermis, the rest of the ear skin was used as dermal samples.
isolated LCs were matured, as previously described. E3 Isolated LCs were seeded at 4 3 10 5 /mL in round-bottom 96-well plates and stimulated with 10 mg/mL IMQ (Tokyo Kasei Industry, Tokyo, Japan) in combination with 1 mg/mL agonistic anti-CD40 antibody (HM40-3; BioLegend) for 5 hours. In some experiments isolated LCs were cultured with or without 100 nmol/L CAL for 29 hours and stimulated for the last 5 hours of culture with IMQ and anti-CD40 antibody.
Statistical analysis
Unless otherwise indicated, results are presented as mean 6 SD values and are representative of at least 3 independent experiments. Comparisons were analyzed for statistical significance by using the Student t test. Statistical significance between multiple groups was analyzed by using the Tukey-Kramer multiple comparisons test. P values of less than .05 were considered significantly different.
J ALLERGY CLIN IMMUNOL VOLUME 141, NUMBER 3 FIG E1. CAL attenuates expression levels of antimicrobial peptides in IMQ-treated ear. Expression levels of S100a7, S100a8, S100a9, and Defb4 mRNA in the ear treated, as indicated for 4 days, is shown. All samples were collected 24 hours after the fourth treatment. Data are shown as each value (symbols) and their means 6 SDs (bars). a.u., Arbitrary units. ***P < .001 and ****P < .0001. 
